Arcus Biosciences, Inc. (RCUS) research
Arcus Biosciences, Inc.- Sector
- Biotechnology
- Last price
- $25.95
- As of
Arcus Biosciences, Inc. (RCUS): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.
As of . Source: SEC EDGAR filings for RCUS. Method and limitations.
Share the RCUS intelligence card
See RCUS live in the terminal
Track RCUS's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live RCUS terminal, freeActive signals for RCUS
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +8305% to RCUS (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 63% of RCUS (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +103% to RCUS (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +8305% to RCUS (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 63% of RCUS (2026Q2)
FREE, NO ACCOUNT
Every signal on RCUS, as it fires
You are seeing 5 of 20 signals recorded on RCUS since 2026-06-01.
The five above all landed on 2026-09-06. The other 15 were recorded on 4 other days. 15 of the 20 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RCUS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 03969F109 · 2026Q2 | $96.7M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 03969F109 · 2026Q2 | $19.6M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 03969F109 · 2026Q2 | $4.1M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 03969F109 · 2026Q2 | $3M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RCUS
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
RCUS against its peers
RCUS's operating margin of -1169.7% ranks in the 23rd percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.
| Metric | RCUS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 33.0M USD | 53.2M USD | 50 | 16 |
| Operating margin | -1169.7% | -361.1% | 23 | 14 |
| Net margin | -1069.7% | -296.2% | 37 | 14 |
| Return on equity | -55.9% | -29.7% | 26 | 24 |
Peers (24): VCYT, DNLI, DYN, CLDX, VKTX, GRTX, QURE, MBX, LEGN, ARQT, GRAL, ZLAB, IDYA, ATAI, IMNM, PHVS, PGEN, NAMS, CPRX, NRIX, IRON, ELVN, MLYS, CELC. Left out: ZLDPF (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (RCUS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more RCUS signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to RCUSand get the insider, 13F, options, and confluence read in one view.